1-(3-chloro-8-fluoro-dibenzo[b,f]thiepin-10-yl)-4-methyl-piperazine | 58912-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 1-(3-chloro-8-fluoro-dibenzo[b,f]thiepin-10-yl)-4-methyl-piperazine
• 英文别名: 1-(9-Chloro-3-fluorobenzo[b][1]benzothiepin-5-yl)-4-methylpiperazine
• CAS: 58912-99-5
• 化学式: C₁₉H₁₈ClFN₂S
• 分子量: 360.883
• InChiKey: IAMLCAUGORULLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  31.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• COMPOSITIONS FOR USE IN THE TREATMENT OF LEUKAEMIA
  申请人：Fundació Institut de Recerca Contra la Leucèmia Josep Carreras

  公开号：EP4000617A1

  公开（公告）日：2022-05-25

  The present invention relates to a method of treating a warm-blooded animal, especially a human subject, having leukaemia, preferably acute myeloid leukemia (AML), B and T acute lymphoblastic leukemias (B-ALL and T-ALL), or chronic myeloid leukemia (CML), or a lymphoma or a solid tumour, comprising administering to said animal a therapeutically effective amount of a compound having any of the formulae identified throughout the present specification, optionally together or in combination with a conventional compound or compound mixture useful in any of said treatments, in particular a topoisomerase II inhibitor, an antimetabolite, or an antitumor antibiotic, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said compound.

  本发明涉及一种治疗患有白血病，优选急性髓性白血病（AML）、B型和T型急性淋巴细胞白血病（B-ALL和T-ALL）或慢性髓性白血病（CML），或淋巴瘤或实体瘤的温血动物，特别是人类受试者的方法，包括向所述动物施用治疗有效量的化合物，该化合物具有本说明书通篇所确定的任何式子、可选地与用于任何所述治疗的常规化合物或化合物混合物，特别是拓扑异构酶 II 抑制剂、抗代谢物或抗肿瘤抗生素，以及可选地至少一种药学上可接受的载体一起或结合使用，可同时、单独或连续使用；以及包含上述化合物的药物组合物和商业包装。
• [EN] COMPOSITIONS FOR USE IN THE TREATMENT OF LEUKAEMIA<br/>[FR] COMPOSITIONS À UTILISER DANS LE TRAITEMENT DE LA LEUCÉMIE
  申请人：[en]FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS

  公开号：WO2022106728A1

  公开（公告）日：2022-05-27

  The present invention relates to a method of treating a warm-blooded animal, especially a human subject, having leukaemia, preferably acute myeloid leukemia (AML), B and T acute lymphoblastic leukemias (B-ALL and T-ALL), or chronic myeloid leukemia (CML), or a lymphoma or a solid tumour, comprising administering to said animal a therapeutically effective amount of a compound having any of the formulae identified throughout the present specification, optionally together or in combination with a conventional compound or compound mixture useful in any of said treatments, in particular a topoisomerase II inhibitor, an antimetabolite, or an antitumor antibiotic, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said compound.